20/20 Biolabs, Inc. (AIDX): Cost of Revenue
$1.44M
Year ended 2025-12-31
$1.40M
Trailing 12 months to 2026-06-30
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.44M | +3.5% | 2026-03-31, From 2025-01-01 |
| 2024-12-31 | $1.39M | n/a | 2026-03-31, From 2024-01-01 |
Cost of Revenue at similar companies
| Company | Year ended | Cost of Revenue | Change YoY |
|---|---|---|---|
| 20/20 Biolabs, Inc. (AIDX) | 2025-12-31 | $1.44M | +3.5% |
| iSpecimen Inc. (ISPC) | 2025-12-31 | $1.90M | -64.1% |
| OneMedNet Corp (ONMD) | 2025-12-31 | $1.86M | +101.5% |
| Cannabis Bioscience International Holdings, Inc. (CBIH) | 2025-05-31 | $40.1K | -12.0% |
| MaxCyte, Inc. (MXCT) | 2025-12-31 | $6.22M | -12.4% |
| NeoGenomics Inc (NEO) | 2025-12-31 | $413.04M | +11.5% |
| UL Solutions Inc. (ULS) | 2025-12-31 | $1.54B | +4.4% |
| Incyte Corp (INCY) | 2025-12-31 | $372.13M | +19.2% |
| Icon PLC (ICLR) | 2024-12-31 | $5.85B | +2.2% |
Compare AIDX, ISPC, ONMD, CBIH side by side · Screen every company in Services-Testing Laboratories ↗